Rao Ramisetti Nageswara
Analytical Chemistry Division, D215, Discovery Lab, Indian Institute of Chemical Technology, Tarnaka, Hyderabad-500607, Andhra Pradesh, India.
Expert Rev Proteomics. 2014 Aug;11(4):425-30. doi: 10.1586/14789450.2014.904204. Epub 2014 Apr 3.
Dried blood spots (DBS), a micro blood sampling technique, has recently gained interest in drug discovery and development due to its inherent advantages over the conventional whole blood, plasma or serum sample collection. Since the regulatory authorities have agreed to the use of blood as an acceptable biological matrix for drug exposure measurements, its applications have been extended not only to therapeutic drug monitoring but also to toxicokinetic and pharmacokinetic studies. The pharmaceutical industry is keen to promote DBS as a prominent tool in bioanalytical applications due to the financial, ethical and organizational issues involved in clinical trials. This could be accomplished due to the latest advances in modern analytical technology, particularly liquid chromatography-mass spectrometry. The present review discusses some of the emerging liquid chromatography-mass spectrometry technologies in improving DBS analysis for its innovative applications in the development of new drugs.
干血斑（DBS）是一种微量血液采样技术，由于其相对于传统全血、血浆或血清样本采集具有内在优势，最近在药物发现和开发中受到关注。由于监管机构已同意将血液用作可接受的生物基质进行药物暴露测量，其应用不仅扩展到治疗药物监测，还扩展到毒代动力学和药代动力学研究。由于临床试验涉及的财务、伦理和组织问题，制药行业热衷于将DBS推广为生物分析应用中的一种重要工具。这得益于现代分析技术的最新进展，特别是液相色谱 - 质谱联用技术。本综述讨论了一些新兴的液相色谱 - 质谱联用技术，这些技术在改进DBS分析以用于新药开发的创新应用方面。
